Catheter Precision secures up to $88M in institutional financing commitments

Catheter Precision (VTAK) announced balance sheet improvements through new institutional capital commitments supporting the Company’s next phase of growth. Fly Flyte, a newly acquired subsidiary of VTAK, is now positioned to execute its expansion strategy with a fully funded growth plan supported by its parent company, Catheter Precision. VTAK has recently completed multiple strategic financings designed to support the Company’s transformation and the expansion of the Flyte aviation platform. The financing also provides capital to fund the Company’s medical device operations. The Company’s recent capital initiatives are expected to support the continued expansion of the Flyte platform and the Company’s broader operational transformation. Capital intended to support: Fleet expansion and aircraft acquisitions Market expansion across additional regional corridors Scaling Flyte’s aviation platform infrastructure Balance sheet simplification Reduction of legacy liabilities Management believes these initiatives position the Company as a more streamlined public company with significant exposure to the rapidly expanding regional aviation market.